LON:RENEReNeuron Group Share Price, Forecast & News

GBX 128.50

-1.50 (-1.15 %)

(As of 06/4/2020 08:04 AM ET)

Add

Compare

Today's Range

125

Now: GBX 128.50▼

133.50

50-Day Range

127.50

MA: GBX 146.64▼

173

52-Week Range

Now: GBX 128.50▼

342

Volume23,545 shs

Average Volume28,700 shs

Market Capitalization£40.91 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company's lead therapeutic candidate is CTX stem cell therapy, which has been completed Phase II clinical trial for the treatment of patients living with chronic disability following stroke, as well as that has been completed Phase I clinical trial to treat limb ischaemia. It is also involved in developing human retinal progenitor cell candidate, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, a blindness-causing disease of the retina, as well as that is in Phase I clinical trial to treat cone-rod dystrophy, an inherited eye disorder; and CTX-derived exosomes, which are nanoparticles released by cells containing various active proteins and microRNAs. ReNeuron Group plc was founded in 1997 and is headquartered in Pencoed, the United Kingdom.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for ReNeuron Group.

3.0 Community Rank

Outperform Votes
ReNeuron Group has received 187 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
ReNeuron Group has received 121 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
ReNeuron Group has received 60.71% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about ReNeuron Group and other stocks. Vote “Outperform” if you believe RENE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RENE will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
ReNeuron Group does not currently pay a dividend.
Dividend Growth
ReNeuron Group does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ReNeuron Group insiders have not sold or bought any company stock.

0.6 Earnings and Valuation

Earnings Growth
Earnings for ReNeuron Group are expected to grow in the coming year, from GBX (78.48) to GBX 0 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ReNeuron Group is -3.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ReNeuron Group is -3.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ReNeuron Group has a P/B Ratio of 2.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

0.73 out of 5 stars

Industry, Sector and Symbol

Stock Exchange LON

Industry Biotechnology

Sub-IndustryN/A

SectorMedical

Current SymbolLON:RENE

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.reneuron.com

Phone+44-20-38198400

Debt

Debt-to-Equity Ratio4.69

Current Ratio3.73

Quick Ratio3.73

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales£6.39 million

Price / Sales6.41

Cash FlowGBX 57.23 per share

Price / Cash Flow2.25

Book ValueGBX 63.50 per share

Price / Book2.02

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Employees62

Outstanding Shares31,833,800

Market Cap£40.91 million

Next Earnings DateN/A

OptionableNot Optionable

Receive RENE News and Ratings via Email

Sign-up to receive the latest news and ratings for RENE and its competitors with MarketBeat's FREE daily newsletter.

ReNeuron Group (LON:RENE) Frequently Asked Questions

How has ReNeuron Group's stock been impacted by COVID-19 (Coronavirus)?

ReNeuron Group's stock was trading at GBX 106 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RENE stock has increased by 21.2% and is now trading at GBX 128.50. View which stocks have been most impacted by Coronavirus.

How were ReNeuron Group's earnings last quarter?

ReNeuron Group Plc (LON:RENE) posted its quarterly earnings data on Friday, December, 6th. The company reported ($12.30) earnings per share for the quarter, topping the Zacks' consensus estimate of ($16.30) by $4.00. View ReNeuron Group's earnings history.

Has ReNeuron Group been receiving favorable news coverage?

News articles about RENE stock have been trending very negative on Thursday, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ReNeuron Group earned a daily sentiment score of -3.2 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the next several days. View the latest news aboutReNeuron Group.

Who are some of ReNeuron Group's key competitors?

Some companies that are related to ReNeuron Group include Faron Pharmaceuticals Oy (FARN), Antibe Therapeutics (ATE), BiomX (PHGE), OncoCyte (OCX), Resverlogix (RVX), Tiziana Life Sciences (TILS), Orgenesis (ORGS), Monash IVF Group (MVF), Burcon NutraScience (BU), Helix Biopharma (HBP), Lineage Cell Therapeutics (LCTX), CorMedix (CRMD), BioTime (BTX), Lineage Cell Therapeutics (LCTX) and Matinas BioPharma (MTNB). View all competitors.

What other stocks do shareholders of ReNeuron Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ReNeuron Group investors own include International Road Dynamics (IRD), Sareum (SAR), ValiRx (VAL), Independent Oil & Gas (IOG), Dignity (DTY), Tri-star Resources (TSTR), Sirius Minerals (SXX), Collagen Solutions (COS), RenovaCare (RCAR) and ReNeuron Group (RNUGF).

Who are ReNeuron Group's key executives?

ReNeuron Group's management team includes the following people:

Mr. Olav Hellebø, CEO & Director (Age 54)
Mr. Michael E. Hunt, CFO, Sec. & Exec. Director (Age 56)
Dr. John David Sinden BA, MA, Ph.D., Founder & Chief Scientific Officer (Age 68)
Dr. Randolph Corteling, Head of Research
Mr. Shaun Stapleton BSc (Hons) MTOPRA, Head of Regulatory Affairs

What is ReNeuron Group's stock symbol?

ReNeuron Group trades on the London Stock Exchange (LON) under the ticker symbol "RENE."

How do I buy shares of ReNeuron Group?

Shares of RENE and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is ReNeuron Group's stock price today?

One share of RENE stock can currently be purchased for approximately GBX 128.50.

How big of a company is ReNeuron Group?

ReNeuron Group has a market capitalization of £40.91 million and generates £6.39 million in revenue each year. ReNeuron Group employs 62 workers across the globe.

What is ReNeuron Group's official website?

The official website for ReNeuron Group is www.reneuron.com.

How can I contact ReNeuron Group?

ReNeuron Group's mailing address is Pencoed Business Park, BRIDGEND, CF35 5HY, United Kingdom. The company can be reached via phone at +44-20-38198400.

This page was last updated on 6/4/2020 by MarketBeat.com Staff